De-Risking The Neurology IND: Lessons From Early FDA Engagement

Neurology IND submissions carry some of the highest development risk in biotech. Complex disease biology, subjective endpoints, variable patient populations, and evolving safety expectations can quickly derail timelines, increase costs, and trigger regulatory setbacks if programs are not aligned early with FDA expectations.

This paper explores how proactive FDA engagement helps sponsors identify and mitigate IND risk before it impacts development momentum. From endpoint selection and biomarker strategy to CMC readiness, safety monitoring, and data integrity, the paper outlines practical strategies for building stronger neurology INDs through early collaboration, cross-functional planning, and operational discipline. Drawing on real-world examples from Alzheimer’s, Parkinson’s, psychiatry, and rare neurological diseases, Veristat demonstrates how integrated regulatory, clinical, and biostatistical expertise can help sponsors reduce uncertainty, strengthen investor confidence, and accelerate progress toward first-in-human studies. Learn how early FDA alignment can help your neurology program move forward with greater clarity, confidence, and regulatory readiness.